Merck (MRK) Share-based Compensation (2009 - 2026)
Merck (MRK) posted quarterly Share-based Compensation of $185.0 million for Q1 2026, down 5.13% year-over-year from $195.0 million in Q1 2025, and down 9.76% quarter-over-quarter from $205.0 million in Q4 2025.
Merck (MRK) Share-based Compensation (2009 - 2026) Analysis & Trends
Merck (MRK) has reported Share-based Compensation for 18 consecutive years, with $185.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation fell 5.13% year-over-year to $185.0 million; the TTM figure through Mar 2026 stood at $810.0 million (up 3.85% YoY), while the FY2025 annual figure was $820.0 million, up 7.75% from the prior year.
- Share-based Compensation retreated to $185.0 million in Q1 2026 per MRK's latest filing, from $205.0 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $216.0 million in Q2 2025 and bottomed at $120.0 million in Q1 2022.
- Historically, Share-based Compensation has averaged $173.6 million across 5 years, with a median of $176.0 million in 2024.
- Annual changes were most pronounced in 2023 — Share-based Compensation climbed 23.36% — and 2026, when it decreased 5.13%.
- Merck's Share-based Compensation stood at $145.0 million in 2022, then advanced by 15.17% to $167.0 million in 2023, then rose by 11.98% to $187.0 million in 2024, then increased by 9.63% to $205.0 million in 2025, then fell by 9.76% to $185.0 million in 2026.
- Business Quant data shows MRK's Share-based Compensation at $185.0 million in Q1 2026, $205.0 million in Q4 2025, and $204.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 651.30 Bn | 630.54 Bn | 17.26 Bn | 458.00 Mn |
| 2 | AbbVie | 468.64 Bn | 462.07 Bn | 12.70 Bn | 166.00 Mn |
| 3 | Merck | 378.89 Bn | 371.74 Bn | 12.21 Bn | 298.00 Mn |
| 4 | Novartis Ag | 300.89 Bn | 293.20 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.36 Bn | 252.46 Bn | 12.86 Bn | - |
| 6 | Amgen | 236.69 Bn | 222.70 Bn | 7.24 Bn | 165.00 Mn |
| 7 | Gilead Sciences | 182.15 Bn | 178.97 Bn | 6.22 Bn | 231.00 Mn |
| 8 | Pfizer | 161.31 Bn | 149.61 Bn | 10.94 Bn | 249.00 Mn |
| 9 | Gsk | 105.67 Bn | 101.50 Bn | 8.24 Bn | - |
| 10 | Sanofi | 54.97 Bn | 47.59 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 298.00 Mn |
| Jun 30, 2026 | 298.00 Mn |
| Mar 31, 2026 | 185.00 Mn |
| Mar 31, 2026 | 185.00 Mn |
| Dec 31, 2025 | 205.00 Mn |
| Dec 31, 2025 | 205.00 Mn |
| Sep 30, 2025 | 204.00 Mn |
| Sep 30, 2025 | 204.00 Mn |
| Jun 30, 2025 | 216.00 Mn |
| Jun 30, 2025 | 216.00 Mn |
| Mar 31, 2025 | 195.00 Mn |
| Mar 31, 2025 | 195.00 Mn |
| Dec 31, 2024 | 187.00 Mn |
| Dec 31, 2024 | 187.00 Mn |
| Sep 30, 2024 | 195.00 Mn |
| Sep 30, 2024 | 195.00 Mn |
| Jun 30, 2024 | 203.00 Mn |
| Jun 30, 2024 | 203.00 Mn |
| Mar 31, 2024 | 176.00 Mn |
| Mar 31, 2024 | 176.00 Mn |